ImmunoGen, Inc. (IMGN) News
Filter IMGN News Items
IMGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMGN News Highlights
- IMGN's 30 day story count now stands at 10.
- Over the past 10 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about IMGN are ADC, BEAT and GENE.
Latest IMGN News From Around the Web
Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.
ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call TranscriptImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good morning, and welcome to ImmunoGen’s Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call. Today’s conference is being recorded. At this time, I’d like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead. […] |
Q4 2022 ImmunoGen Inc Earnings CallQ4 2022 ImmunoGen Inc Earnings Call |
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., March 01, 2023--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene EditingImmunoGen Inc (NASDAQ: IMGN) announced a global, multi-target license and option agreement that granted Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rights for ImmunoGen's ADC technology to discover targeted conditioning agents for use with gene editing. After each target's research period, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target. ImmunoGen will retain f |
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue EstimatesImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
ImmunoGen Reports Recent Progress and 2022 Financial ResultsWALTHAM, Mass., March 01, 2023--ImmunoGen Reports Recent Progress and 2022 Financial Results |
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning AgentsWALTHAM, Mass., March 01, 2023--ImmunoGen Announces Global, Multi-Target Agreement with Vertex for Use of ImmunoGen's ADC Tech for Development of Novel Targeted Conditioning Agents |
ImmunoGen Announces Webcasts of Presentations at Upcoming ConferencesWALTHAM, Mass., February 22, 2023--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences |
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out forImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Here’s Why ClearBridge Multi Cap Growth Strategy Exited ImmunoGen (IMGN)ClearBridge Investments, an investment management firm, released its fourth-quarter 2022 “ClearBridge Multi Cap Growth Strategy” investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 3000 Growth Index benchmark. The Strategy gained in six of the seven sectors on an absolute basis in which it was […] |